Von Hippel‑Lindau Disease: Evidence‑Based Surveillance and Management Guidelines

Diagnosis and Genetic Testing

• Genetic confirmation is the definitive diagnostic method for VHL and should be offered to first‑degree relatives of individuals with a pathogenic VHL variant. 1, 2
• Children presenting with any VHL‑associated lesion (retinal angioma, CNS hemangioblastoma, clear‑cell renal carcinoma, pheochromocytoma/paraganglioma, endolymphatic‑sac tumor, epididymal/adnexal papillary cystadenoma, multiple pancreatic cysts or neuroendocrine tumors, or multiple renal cysts) should undergo genetic testing. 1, 3
• Clinical diagnosis without genetic testing is acceptable when (1) there is a known family history of VHL plus a CNS/retinal hemangioblastoma, pheochromocytoma, or renal carcinoma, or (2) a simplex case exhibits either two hemangioblastomas, two visceral tumors, or one hemangioblastoma together with one visceral tumor. 2, 4

Organ‑Specific Surveillance

Ophthalmologic Surveillance

• Begin retinal screening within the first year of life and continue lifelong; examinations are performed every 6–12 months until age 30, then at least annually. 5, 6
• Perform pre‑conception screening and repeat examinations every 6–12 months throughout pregnancy. 5, 6
• Ultra‑widefield color fundus photography and fluorescein angiography are recommended to detect small retinal hemangioblastomas. 5, 6
• Prompt treatment of extramacular or extrapapillary retinal hemangioblastomas is advised to prevent irreversible vision loss. 5, 6
• Lifetime risk of retinal hemangiomas is estimated at 25–60 %; the earliest reported diagnosis occurs at birth, and children are especially prone to severe retinal damage if detection is delayed. 1, 2, 7

Pheochromocytoma Surveillance

• Annual measurement of plasma‑free metanephrines or urine fractionated metanephrines should start at age 5 (some protocols recommend initiation at age 2 due to cases diagnosed as early as 2 years). 1
• Conduct annual abdominal ultrasound between ages 8–15, followed by alternating ultrasound and MRI annually from age 16 onward. 1
• The lifetime risk of pheochromocytoma is 10–25 % with a mean age at diagnosis of 27 years. 1, 3

Central Nervous System (CNS) Hemangioblastoma Surveillance

• Initiate annual brain and spine MRI between ages 8–14 and continue yearly thereafter (biennial imaging is insufficient). 1
• Lifetime risk of CNS hemangioblastomas is 60–80 %; the youngest reported case occurs at age 9, with a mean diagnostic age of 30 years. 1, 2

Renal Surveillance

• Begin annual abdominal ultrasound or MRI at age 16 to monitor renal involvement. 1
• Renal manifestations occur in 25–75 % of individuals, with renal cell carcinoma (RCC) risk ranging from 17–70 %; the earliest RCC diagnosis is reported at age 13, and the mean age is 44 years. 1, 3

Endolymphatic‑Sac Tumor (ELST) Surveillance

• Perform audiologic evaluation every 2–3 years from ages 5–15, then every 2 years from age 15 onward. 1
• ELSTs have a lifetime risk of 10–15 %, with the youngest documented case at age 6. 1

Pancreatic Surveillance

• Annual abdominal imaging (ultrasound or MRI) should start at age 16 to assess pancreatic lesions. 1
• Pancreatic cysts and neuroendocrine tumors develop in 35–75 % of patients; the earliest cyst is identified at age 5 and the earliest neuroendocrine tumor at age 16. 1, 3

Surgical Management

• VHL‑related tumors are generally resected when they become symptomatic or reach size thresholds that increase operative risk. 7
• Early detection of CNS hemangioblastomas enables surgical excision with minimal surrounding tissue injury. 1, 2
• Prompt treatment of extramacular/extrapapillary retinal hemangioblastomas prevents permanent vision loss. 5, 6

Common Pitfall

• Delaying surgery until severe symptoms develop is associated with higher rates of intra‑operative hemorrhage (particularly for large CNS hemangioblastomas) and irreversible organ damage. 1, 7

Multidisciplinary Care

• Management should be coordinated within specialized multidisciplinary centers staffed by subspecialists experienced in VHL, ensuring comprehensive multiorgan surveillance and access to genetic testing. 5, 6
• A designated coordinating physician is recommended to oversee referrals and inter‑team communication. 5, 6

Epidemiology and Prognosis

• Lifetime penetrance of VHL approaches 100 % by age 75; inheritance is autosomal dominant with approximately 80 % of cases inherited and 20 % de novo. 2, 4
• Although most VHL‑associated tumors are histologically benign, morbidity from mass effect and surgical complications can be substantial. 7, 3

Comprehensive, evidence‑based surveillance programs have demonstrably reduced mortality from RCC, pancreatic neuroendocrine tumors, and CNS hemangioblastomas by facilitating early detection and timely multidisciplinary intervention. 1, 7, 2

Surgical Technique and Peri‑operative Management in Renal Transplantation for Von Hippel‑Lindau Disease

Surgical Approach Planning

• Standard open kidney transplantation should be performed using an end‑to‑side arterial anastomosis to the external or common iliac artery, or an end‑to‑end anastomosis to the internal iliac artery in VHL patients undergoing their first renal graft. 8
• For VHL patients who may require a third or subsequent renal transplant, pre‑operative imaging must assess arterial inflow, venous outflow, and available pelvic space to ensure adequate graft placement. 8

Peri‑operative Antibiotic Prophylaxis

• A single dose of peri‑operative antibiotic prophylaxis is recommended, following standard transplant protocols, to reduce the risk of early postoperative infection in VHL transplant recipients. 8

Post‑Transplant Surveillance (Graft‑Specific)

• Routine post‑transplant monitoring for acute rejection, infection, and graft dysfunction should be conducted according to established transplant surveillance guidelines, without modification for VHL status. 8

Monitoring for Surgical Complications

• Surveillance for arterial thrombosis—a complication occurring in approximately 0.5 % to 3.5 % of all kidney transplant recipients—should be incorporated into the postoperative care plan for VHL patients. 8